It’s been a rough couple of days for Merck (MRK, $31.33, down $4.00). The stock followed Monday’s 6% decline with a 11% drop on Tuesday after lackluster earnings and some damaging information for the company’s cholesterol drug Vytorin. On Monday when Merck was at $36, I mentioned that earnings wereRead more

More